Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Kailua-Kona, Hawaii. Mera Pharmaceuticals, Inc. primarily develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology known as the Mera Growth Module. Mera Pharmaceuticals company's product line consists of ASTAFACTOR, a nutraceutical and source of natural astaxanthin; and SALMON ESSENTIALS, a combination of astaxanthin and omega-3 fatty acids. It markets its products to retail outlets in Hawaii through distribution arrangements with established companies.

Kreatech Biotechnology company develops tools used by pharmaceutical companies and medical researchers to detect and label RNA, DNA, and proteins. Its labeling kits, DNA probes, and other products are used in applications such as drug development and the diagnosis of disease. The company's investors include 3i Group, Alafi Capital, and Life Sciences Partners. Kreatech has formed alliances with many pharmaceutical and instrumentation firms, including heavyweights such as GE Healthcare Bio-Sciences and PerkinElmer.

Sunesis Pharmaceuticals, Inc. company was founded in 1998 and is headquartered in South San Francisco, California. Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumor cancers. Its primary product candidate is Voreloxin, an anticancer quinolone derivative (AQD) for the treatment of cancer in Phase 2 development stage. The company is conducting various clinical trials of Voreloxin, including a Phase 2 clinical trial, known as the REVEAL-1 trial, in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in advanced platinum-resistant ovarian cancer patients. Sunesis Pharmaceuticals has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and marketing of Voreloxin.

Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York. Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company's commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical trials include Aflibercept for the treatment of oncology; VEGF Trap-Eye in wet AMD in patients for eye diseases; and ARCALYST versus placebo for the prevention of gout flares in patients initiating urate-lowering drug therapy. The company's products under clinical trials include REGN88, an antibody to the Interleukin-6 receptor (IL-6R) that is being evaluated in patients with rheumatoid arthritis; REGN421, an antibody to delta-like ligand-4 that is being developed for oncology; and REGN475, an antibody to nerve growth factor, which is being developed for the treatment of pain. Regeneron Pharmaceuticals also conducts other preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, and cardiovascular diseases. The company has strategic collaboration agreements with sanofi-aventis Group to discover, develop, and commercialize fully human monoclonal antibodies; and Bayer HealthCare LLC for the development of the VEGF-Trap-Eye.

Dainippon Sumitomo Pharma (DSP) is Osaka's answer to disease. The Japanese drugmaker produces drugs in a wide range of therapeutic categories including cardiovascular disease, gastrointestinal disorders, and infections. Its products include blood pressure medication Amlodin, digestive tract treatment Gasmotin, and antibiotic Meropen. Subsidiary Sepracordevelops and markets central nervous system and respiratory drugs in North America; its top selling product is insomnia therapy Lunesta. In addition to pharmaceuticals, DSP makes food and feed additives, veterinary drugs, fine chemicals, and diagnostic reagents used in research and clinical laboratories. Sumitomo Chemical owns just over half of DSP.

Nycomed International Management GmbH the Swiss pharmaceutical company develops presciption and OTC medicines mainly focusing on cardiology, gastroenterology, osteoporosis, respiratory, and pain management therapies. It operates nearly 20 facilities in a dozen European countries, where it conducts its own research and drug testing. It also develops products in conjunction with partner pharmaceutical companies. The majority of Nycomed's revenues come from direct drug sales to doctors, hospitals, and pharmacies in Europe, the Americas, Russia, and Asia/Pacific as well as from licensing product rights to and from other companies.

Natrol, Inc. company was founded in 1980 and is headquartered in Chatsworth, California. Natrol, Inc. manufactures and distributes nutritional products. The company offers nutritional and dietary supplements, functional herbal teas, and sports nutrition products for heart and digestive health, weight management and energy, mood and sleep support, eye and joint health, and children's and brain health. It also provides Natrol Immune Boost for the wellness of bodys immune system. In addition, the company manufactures supplements for third parties. It offers its products through retailers in the United States and subsidiaries in the United Kingdom and Hong Kong, as well as through distribution partners internationally.

FAES was founded in 1933. Faes Farma SA is a Spanish company primarily engaged in the research, manufacture and commercialization of pharmaceutical products, such as prescription drugs, over-the-counter medicines and skin-care treatments, as well as raw materials used in the pharmaceutical industry. The Company’s facilities include one research and development center and three manufacturing plants, which are located in the cities of Leioa, Lisbon and Madrid. The Company is a parent of Grupo Faes, a group which comprises Laboratorios Vitoria SA, Laboratorios Veris SA, Iquinosa Farma SA, Lazlo International SA, Hispana Dos SA SICAV, Ingaso Farm SLU, Biotecnet I MAS D SA, Esfion SA, Olve Farmaceutica Lda, Veris Farmaceutica Lda, Vitalion Lda and Farmalavi Lda. Through its subsidiaries, the Company operates mainly in Spain and Portugal. It also has presence in approximately 50 countries in Europe, America, Africa and Asia.

Don and Lucy Hillestad founded Hillestad Pharmaceuticals USA, Inc. in 1959. Hillestad Pharmaceuticals USA goes natural, producing vitamin, mineral, protein, and herb products from all-natural sources. It also makes prescription and nonprescription vitamin products for dialysis patients under the Dialyvite and Hill*Vite names. In addition, Hillestad offers private-label manufacturing of tablets, powders, cremes, lotions, and liquids for doctors and pharmacies, health food stores, and various national and international companies.

OXiGENE, Inc. company was founded in 1988 and is headquartered in Waltham, Massachusetts. OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.